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RNA therapeutics mainly control gene expression at the transcript level. In contrast to conventional gene
therapy which solely increases production of a protein, delivered RNAs can enhance, reduce or abolish
synthesis of a particular protein, which control its relevant activities in a more diverse fashion. Thus, they
hold promise to treat many human diseases including myocardial infarction (MI). MI is a serious health
burden that causes substantial morbidity and mortality. An unmet clinical need for treating MI is the
recovery of cardiac function, which requires regeneration of the functional tissues including the
vasculature, nerves, and myocardium. Several classes of RNA therapeutics have been investigated in
preclinical MI models, and the results have demonstrated their beneﬁts and encourage their future
development. In this review, we summarize the common RNA therapeutic approaches and highlight
their application in MI therapy.
© 2016, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Regeneration of human tissue after injury is a challenging goal
and relies on the careful control of several key factors. First and
foremost is the capacity of viable cells to proliferate and repopulate
the damaged area. If they fail to fulﬁll this role, recovery cannot be
initiated and the function of the organ often becomes worse over
time. This is a common issue preventing recovery after MI. MI, thesting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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of a coronary artery [1,2]. Because the blood supply is blocked, MI
results in immediate death of cardiomyocytes. Subsequent com-
plications such as oxidative stress and inﬂammation cause sec-
ondary damage that further deteriorates cardiac contractility [3].
Recovery from MI is extremely difﬁcult for two main reasons: (i)
human cardiomyocytes have very limited proliferative potential
[4]; (ii) the dysfunctional coronary vasculature and inﬂammation
associated with MI create an unfavorable environment for the
remaining cardiomyocytes to survive. Dead cardiomyocytes are not
replenished, leading to a reduction in cardiac contractility that is
not naturally reversible. Apart from heart transplantation, current
treatments for MI only restore the blood supply to residual car-
diomyocytes, but do not improve function. New therapeutic ap-
proaches to repair damaged myocardium more effectively and
prevent recurrent MI are of great interest [5].
Presently, the most promising alternative treatments include
protein delivery, gene delivery and cell delivery which are each in
various stages of clinical development [6,7]. Protein delivery is
considered to be the most straightforward approach in which
therapeutic proteins such as growth factors are applied to regen-
erate de novo cardiac tissues [8]. However, their efﬁcacy is often
compromised by their short in vivo half-lives. Gene delivery results
in a stronger and longer-lasting therapeutic effect compared to
protein therapy; nevertheless, unregulated overproductionmust be
prevented to avoid adverse effects [9]. In comparison to protein and
gene therapies, cell therapy can directly replace the dead cells or
secrete various factors to promote cardiac regeneration [10].
However, acquiring adequate numbers of cells, on the order of
millions per patient, is a signiﬁcant challenge and their in vivo
viability is usually very low. In recent years, RNA-based therapies
have been examined in many human disease models including
those mimicking human cardiovascular diseases. Distinct from
conventional gene therapies that employ DNA to produce a thera-
peutic protein, RNA-based approaches affect cellular activity in a
more diverse fashion as they can increase or decrease the level of a
protein. In this review, we summarize the different categories of
RNA therapeutics and highlight their potential for treating coronary
heart disease.
2. RNA therapeutics
RNA-based approaches to cardiac regeneration are promising
and offer several unique beneﬁts because of their ability to
modulate production of speciﬁc proteins at the transcriptional
level [11]. Since a single transcript makes hundreds or thousands
of copies of a protein, therapies targeting transcripts may have
greater and more widespread effects compared to small molecule
drugs or recombinant proteins [12]. Yet the development of RNA
therapeutics is still in its infancy. The only RNA drugs approved by
the FDA are fomivirsen, an antisense oligonucleotide mitigating
cytomegalovirus retinitis, and pegaptanib, an aptamer antagonist
of vascular endothelial growth factor used to treat neovascular
age-related macular degeneration [13,14]. RNA therapeutic agents
including mRNA, small interfering RNA, microRNA and ribozymes
are currently in clinical trials. Compared to DNA which is highly
stable, RNA is unstable due to several structural differences that
can dramatically compromise the efﬁcacy of RNA therapeutics: (i)
the hydroxyl group on the C2 position of the ribose can be
deprotonated in alkaline conditions and act as a nucleophile to
cleave the phosphodiester bond; (ii) RNAs have larger major
grooves where nucleases can dock [15]; (iii) exogenous RNAs can
activate innate immunity and trigger interferon-mediated re-
sponses such as suppression of translation and upregulation of
ribonucleases [16]. A common strategy to minimize thedegradation and immunogenicity of RNAs is to build them from
modiﬁed nucleotides. For example, RNAs made from base analogs
such as 5-methylcytosine (m5C) and pseudouridine (J) are less
likely to be recognized by nucleases and immunoreceptors
including Toll-like receptor (TLR) 3, TLR7 and TLR8 [17]. Thus,
in vivo half-lives can be prolonged [18].
Another factor that determines the efﬁcacy of a therapeutic
RNA agent is its mode of delivery. Naked RNAs delivered sys-
temically or locally are cleared rapidly and thus a targeted delivery
mechanism is critical to protect it from degradation and to pro-
mote its accumulation at the desired site [19]. In vivo delivery
(transfection) is accomplished utilizing viral vectors or synthetic
vehicles. Virus-mediated transfection, also called transduction,
typically has high efﬁciency although safety is a major concern
[20]. Non-viral synthetic vehicles are cationic lipids or polymers
which interact with the phosphate groups of RNA molecules and
self-assemble into stable complexes. Additional to cytotoxicity of
the vehicle, lower efﬁciency compared to viral vectors presents an
additional design challenge [21]. Therefore, signiﬁcant efforts have
been devoted to improving cell targeting and internalization of
RNA agents, two key factors constituting the efﬁciency of the
synthetic vector [22e24].
The route of administration also plays an important role in the
therapeutic efﬁcacy. In the common small animal MI models, a left
thoracotomy is performed to induce MI followed by local injection
of a therapeutic agent. In this fashion, a maximal amount of ther-
apeutic agent can be accumulated in the infarcted region. However,
this surgical procedure is highly invasive and is only applied in
patients that require advanced procedures such as coronary artery
bypass grafting. Administration of RNA therapeutics in patients
would largely be done by parenteral routes. Systemic injection re-
quires a delivery vehicle that selectively and efﬁciently targets an
MI-associated biomarker [25]. Local injection avoids rapid clear-
ance of RNA by the circulation but requires a device to reach the
myocardium. Catheter-based injection has been employed to
deliver genes, proteins and cells, and would be feasible for delivery
of RNA therapeutic agents as well [26]. The current progress and
future directions in nucleic acid delivery have been discussed in
many reviews [27e29].3. RNA therapeutic agents in cardiac repair
The common classes of therapeutic RNAs and their status of
development are summarized in Table 1. Themajority of such RNAs,
with the exception of mRNA, are non-coding RNAs that regulate
cellular functions by various mechanisms [30]. Many other non-
coding RNAs are not discussed here as their functions and thera-
peutic value are not fully understood. Similar with gene- and
protein-based therapies for MI, therapeutics RNAs are under
investigation for three purposes: (i) induction of neovasculature:
MI leads to an ischemic environment that deteriorates the cardiac
function over time [31]. Formation of new blood vessels by intro-
ducing angiogenic growth factors is considered a promising
approach to repair damaged vasculature and restore blood supply.
(ii) Reversal of the harsh environment: pathophysiological condi-
tions such as inﬂammation are responsible for continuing necrosis
and apoptosis of cardiomyocytes after MI [32]. A therapeutic agent
that corrects the diseased condition is beneﬁcial for preserving
remaining cardiomyocytes and cardiac contractility. (iii) Applica-
tion in stem cell therapy: stem cells have the capability of regen-
erating cardiac tissues including functional myocardium and
vasculature. Therapeutics that effectively control the activities of
stem cells including survival and differentiation are of great
importance to move this ﬁeld forward [33]. Here, we describe the
Table 1
Current development of RNA therapeutics.
Function Size (nt) Status of development
messenger RNA (mRNA) RNA transcript encode a protein
sequence
400e12,000 Phase 2 trials in cancer immunotherapy [34]
antisense oligonucleotide Pair with an mRNA target to
inactivate translation
15e25 Fomivirsen approved for cytomegalovirus retinitis [35]
ribozyme Recognize and catalyze cleavage of
an mRNA target
50e150 Phase 2 trials in Human Immunodeﬁciency Virus 1 infected patients [36]
aptamer Bind and inhibit a molecular target 70e80 Pegaptanib approved for neovascular age-related macular degeneration [37]
small interfering RNA Pair with the coding region of a
target mRNA to induce cleavage
20e30 Most in phase 1 and 2 trials; a phase 3 trial terminated early due to the poor result [38]
microRNA Pair with the 30 untranslated region
of a target mRNA to induce cleavage
20e30 Phase 1 and 2 trials in cancer treatment [39]; phase 3 trials in cancer diagnosis [40]
guide RNA Pair with a DNA target to direct a
site-speciﬁc cleavage
100 Experimental studies only thus far
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their progress individually.3.1. messenger RNA (mRNA)
Conventional gene therapy delivers DNA into cells to produce a
functional protein to replace a deﬁcient or dysfunctional one. This
approach still has several drawbacks that limit its therapeutic ef-
ﬁcacy. For example, nonviral approaches using synthetic vehicles to
deliver DNA have difﬁculty crossing barriers including the plasma
and nuclear membranes to reach the nucleus where transcription
occurs. Using viral vectors as carriers has better efﬁciency, but their
immunogenicity raises safety concerns. Delivered DNA also has the
potential risk of chromosomal integration, which could lead to gene
overexpression and undesired effects such as tumorigenesis.
mRNA-based therapy can avoid the above issues because it func-
tions in the cytoplasm, leading to the following advantages: (i)
delivery is more efﬁcient to the cytosol than to the nucleus; (ii)Fig. 1. Modiﬁed mRNA reduces immunogenicity and reveals a better therapeutic outc
interferon-a in mice with intravenous injection of unmodiﬁed mRNA or modiﬁed mRNA, or
2SU. S2U(0.25)m5C(0.25): modiﬁed mRNA in which 25% of uridine was replaced by 2SU and 25
signiﬁcantly lower levels of cytokine secretion. *p < 0.05. Reprinted from ref. [33] with perm
plasmid encoding VEGF-A. Transfection of modiﬁed mRNA (modRNA) resulted in quick pro
transfection of the plasmid (DNA) had a much longer effect as high levels of VEGF-A were
comparison of vascular density in the infarct area of the murine heart at 7 days post injury.
VEGF-A modRNA: modiﬁed mRNA encoding VEGF-A; VEGF-A DNA: the plasmid encoding V
blood vessels than other groups. Reprinted from ref. [38] with permission.mRNA does not integrate into the host genome, obviating several
safety concerns; (iii) the response is more rapid than for DNA, as
mRNA is directly utilized for protein synthesis [41].
Therapeutic mRNA is prepared by in vitro transcription, inwhich
an RNA polymerase from a bacteriophage drives transcription from
a DNA template [42]. Design of the DNA template is critical as it
affects the stability of transcribed mRNA. For example, the 30 un-
translated region of a-globin is frequently incorporated to stabilize
mRNA [43]. The length of the poly(A) tail also affects the stability
and translation of mRNA signiﬁcantly [44]. mRNA that can be
thousands of nucleotides in length has more prominent immuno-
genicity than short RNAs. The immunogenicity of mRNA is only
beneﬁcial when it is used as a vaccine against an infections disease
or cancer [45]. In most cases, mRNA is synthesized with modiﬁed
nucleotides to reduce immunogenicity; the resulting mRNA is
termed modiﬁed mRNA. Modiﬁed nucleotides m5C, 2-thiouridine
(2SU) and J are commonly used because they reduce mRNA
recognition by TLRs (Fig. 1A) [46].ome than DNA in a MI model. (A) Plasma levels of interferon-g, interleukin-12 and
without treatment. S2U(0.5): modiﬁed mRNA in which 50% of uridine was replaced by
% cytosine was replaced by m5C. The results suggested that modiﬁed mRNA resulted in
ission. (B) Production of VEGF-A in cardiac cells transfected with modiﬁed mRNA or the
duction of VEGF-A and its level decreased to the basal level after 3 days. In contrast,
still detected after 6 days. Reprinted from ref. [38] with permission. (C) Macroscopic
vehicle (control): no treatment; Luc modRNA: modiﬁed mRNA encoding the luciferase;
EGF-A. The representative images revealed that the VEGF-A modRNA group had more
H. Chu et al. / Regenerative Therapy 4 (2016) 83e9186Therapeutic mRNA can be delivered by ex vivo or in vivo trans-
fection and both approaches have entered clinical trials [47].
Immunotherapy utilizes ex vivo delivery, in which autologous cells
(e.g. dendritic cells) are collected and transfected with tumor or
viral mRNA, then returned to the patient's body [48]. The advantage
of ex vivo delivery lies in the high degree of control over trans-
fection method and conditions [49]. In contrast, direct injection of
mRNA to achieve in vivo transfection is more straightforward and
avoids elaborate processes of cell collection. Yet the outcome may
be subject to higher patient-to-patient variability due to uncon-
trollable factors [50].
mRNA could be designed for different therapeutic outcomes
when treating MI. For example, mRNA targeted to the proper cell
type could produce proteins to: (i) promote vascularization of the
myocardium; (ii) reduce inﬂammation of the damaged myocar-
dium; (iii) produce de novo cardiac tissues. For instance, Elmadbouh
I et al. transfected skeletal myoblasts to produce stromal cell-
derived factor-1a and their transplantation in the infarcted
myocardium promoted stem cell homing and angiomyogenesis
[51]. Zangi L et al. compared production of vascular endothelial
growth factor-A (VEGF-A) in cardiomyocytes by in vivo transfection
of modiﬁed mRNA or a plasmid found that expression proﬁles were
quite different (Fig. 1B) [52]. Modiﬁed mRNA led to a pulse-like
production of VEGF-A as the greatest amount of VEGF-A was
detected in the ﬁrst 8 h post-transfection and was barely detectable
after 48 h. In contrast, the plasmid prolonged expression for over
one week. Intriguingly, in this mouse MI model, injection of VEGF-
A-encoding modiﬁed mRNA resulted in a better cardiac function
along with functional vasculature, compared to the plasmid-
mediated treatment (Fig. 1C). One possible reason could be that
transient production of VEGF-A is more favorable to differentiate
epicardial progenitor cells into endothelial cells [53].
Reducing inﬂammation is another promising strategy to treat MI
and other cardiovascular diseases [54]. For example, Levy O et al.
engineered autologous mesenchymal stem cells with a tissue-
targeting ligand and immuno-modulatory capability [55]. Upon
re-injection, engineered cells found the inﬂamed endothelium and
effectively reduced inﬂammation by secreting anti-inﬂammatory
cytokines.
mRNA delivery has also been examined in cell reprogram-
ming. For example, Warren L et al. generated induced pluripotent
stem cells (iPSCs) by modiﬁed mRNA encoding four reprogram-
ming factors, c-Myc, Klf4, Oct4, and Sox2, which could be later
differentiated into any cell types including cardiomyocytes and
endothelial cells [56]. An interesting feature of this approach is
the high efﬁciency, as Schlaeger TM et al. found that modiﬁed
mRNA produced more iPSCs compared to two other non-
integrating methods, Sendai viral and episomal vectors. The
limitation is that repeated transfection was required to maintain
the production of reprogramming factors, which again reﬂects
the short half-life of mRNA. In recent years, direct reprogram-
ming (transdifferentiation) has drawn more attention as it by-
passes long procedures to produce iPSCs [57]. Lee K et al.
revealed that efﬁcient delivery of modiﬁed mRNA encoding
Gata4, Mef2c, and Tbx5 could directly differentiated cardiac ﬁ-
broblasts into cardiomyocyte-like cells, which express functional
markers as endogenous cardiomyocytes [58].
3.2. Small interfering RNA (siRNA)
siRNAs are double-stranded RNA fragments (20e30 nucleo-
tides) that direct a post-transcriptional gene silencing process
called RNA interference (RNAi). RNAi was originally observed in the
worm Caenorhabditis elegans and was later revealed to be present
in mammals against viral infection. It functions by pairing a single-stranded siRNA (ss-siRNA) with the complimentary sequence in a
target mRNA followed by endonucleolytic mRNA cleavage. RNAi to
target any gene can be introduced by several methods. For example,
a plasmid can be transfected to express a short hairpin RNA
(shRNA). The shRNA is processed endogenously into the ss-siRNA
and is incorporated into the RNAi speciﬁcity complex (RISC),
which directs degradation of a target mRNA in the cytosol [59].
Another method to bypass transcription is to deliver RNAs (shRNAs,
siRNAs or ss-siRNAs) into a cell, which would then be processed
and incorporated into RISC [60].
siRNA-induced RNAi has become a powerful tool for deciphering
molecular mechanisms of cardiovascular diseases and uncovering
new therapeutic targets [61,62]. In terms of therapy, siRNAs that
inhibit key proteins overproduced in cardiovascular disorders have
shown great promise. For instance, the enzyme proprotein con-
vertase subtilisin/kexin type 9 (PCSK9) increases the level of
cholesterol in plasma and PCSK9 inhibition is considered a thera-
peutic strategy to ameliorate hypercholesterolemia [63]. Frank-
Kamenetsky M et al. demonstrated that lipidoid nanoparticles
delivering the siRNA against PCSK9 effectively lowered cholesterol
in monkeys [64]. In a mouse MI model, Majmudar MD et al.
employed an siRNA to silence the chemokine receptor CCR2 and
improvedMI recovery by reducing inﬁltration of inﬂammatory cells
into the infarcted area [65]. In addition to inﬂammation, car-
diomyocyte apoptosis also reduces cardiac contractility. Apoptosis
post-MI is mediated in part by tyrosine phosphatase Src homology
region 2 domain-containing phosphatase 1 (SHP-1) [66]. Kim D
et al. reported that RNAi against SHP-1 could rescue car-
diomyocytes in a mouse MI model [67]. Off-target binding of siR-
NAs represents a hurdle in this ﬁeld as it can lead to non-speciﬁc
gene silencing [68]. A variety of approaches have been investigated
to reduce off-targeting effects including the tough decoy (TuD) RNA
which is introduced to inhibit the sense strand of the siRNA duplex
(Fig. 2A) [69,70].
3.3. microRNA (miRNA)
Similar to siRNAs, miRNAs are short nucleotides that induce
RNAi to repress expression of a gene. Three characteristics distin-
guish miRNA-from siRNA-mediated gene silencing: (i) miRNAs are
endogenous non-coding RNAs that play an essential role in con-
trolling cellular processes while siRNAs are artiﬁcial constructs
introduced to knock down a gene; (ii) a miRNA usually targets the
30-untranslated region of mRNA while siRNA targets the coding
region; (iii) more importantly, miRNA-mediated gene silencing
does not require perfect sequence complementarity as does siRNA-
mediated gene silencing. Biogenesis of miRNAs follows a series of
steps. A long transcript called the primary miRNA (pri-miRNA) is
synthesized by RNA polymerase II, which is then processed by the
RNase Drosha into a 60- to 100-nt shRNA also called pre-miRNA.
After transport into the cytoplasm, the pre-miRNA is further pro-
cessed by another RNase, Dicer, into the mature miRNA (20e30 nt).
Like siRNAs, an exogenous miRNA can be introduced into a cell by a
viral vector encoding pre-miRNA or by a synthetic vehicle carrying
synthetic pre-miRNA or miRNA [71,72].
miRNA research is a relatively recent development but its
importance has been revealed in many human diseases including
coronary heart disease (Table 2) [73]. In one example,
cardiomyocyte-speciﬁc deletion of dgcr8, a gene required for
miRNA production, led to ventricular malfunction and premature
lethality [74]. In another, miRNA-21 (miR-21) was revealed to
promote cardiac ﬁbrosis by upregulating the ERK-MAP kinase
signaling pathway in cardiac ﬁbroblasts [75]. Suppression of miR-
21 activity by a miRNA inhibitor (anti-miR) signiﬁcantly reversed
this outcome and improved cardiac function. Another important
Fig. 2. RNAi and CRISPR/Cas9 alleviate cardiovascular diseases by speciﬁcally repressing diseased genes. (A) Co-expression of the shRNA and TuD RNA to reduce off-target
effects: TuD RNA contained an internal loop with two regions complimentary to the antisense strand of the therapeutic shRNA duplex. Consequently, the activity of the anti-
sense strand was inhibited and only the sense strand was allowed to recognize a target mRNA. Reprinted from ref. [56] with permission. (B) The bar graph and representative
pictures compared the size of infarct area at 14 days after MI surgery. Ad.Null: empty vector; Ad.decoymiR-24: adenoviral vector carrying a decoy sequence for miR-24. The result
revealed that inhibition of miR-24 decoy signiﬁcantly decreased the infarct size. *p < 0.05. Reprinted from ref. [66] with permission. (C) Serum levels of PCSK9 and total cholesterol
in mice after receiving no treatment or different titers of adeno-associated virus vectors that encode Cas9 and the Pcsk9-targeting guide RNA (Pcsk9-sg1) or the control RNA (Rosa-
sg1). The result suggested that knockout of Pcsk9 reduced 95% of Pcsk9 and 40% of total cholesterol, and reductions sustained throughout the study. **p < 0.01. Reprinted from ref.
[93] with permission.
H. Chu et al. / Regenerative Therapy 4 (2016) 83e91 87miRNA involved in cardiac ﬁbrosis is miR-101 [76]. Increasing its
level was found to mitigate ﬁbrosis by reducing production of
collagen. Similarly, a decrease in miR-29 after MI induced produc-
tion and deposition of collagen ﬁbers [77]. miRNAs are also closely
associated with other regenerative processes in the heart [78,79].
Taken together, delivery of miRNA or anti-miR has great potential
as a therapy for a variety of diseases [80,81].
miRNA-based therapeutics in cardiovascular diseases can be
used in three different strategies: (i) modulation of microenviron-
ment: Meloni M et al. expressed a decoy against miR-24 to reverse
its inhibition on angiogenesis and to improve cardiac function in a
mouse MI model (Fig. 2B) [82]; (ii) ex vivo cell modiﬁcation: Glass C
& Singla DK observed that overexpressingmiR-1 in embryonic stem
cells (ESCs) improved their differentiation into cardiomyocytes and
reduced levels of apoptosis following injection in the infarcted
heart [83]; Huang L et al. overexpressed miR-126 in mesenchymal
stem cells and transplanted them in the infarcted myocardium toTable 2
Representative miRNAs implicated in coronary heart disease.
Implication in coronary heart disease miRNAs
Atherosclerosis [88] miR-21, mi
Angiogenesis [89] Let-7f, miR-
Cell proliferation/death [90] miR-1, miR
Cardiac remodeling [91] miR-1, miR
Cardiac development [92] miR-1, miRimprove angiogenesis and overall cardiac function [84]; (iii) in vivo
cell reprogramming: Anokye-Danso F et al. showed that lentiviral
transduction of murine embryonic ﬁbroblasts to express the miR-
302/367 cluster resulted in higher iPSC production efﬁciency than
the standard method using four transcriptional factors [85]; Addi-
tionally, Jayawardena TM et al. revealed that treatment with len-
tiviruses encoding miR-1/133/208/499 enabled direct in vivo
conversion of cardiac ﬁbroblasts into cardiomyocyte-like cells in
the infarcted heart [86]. The subsequent functional study further
demonstrated that these cardiomyocyte-like cells could signiﬁ-
cantly improve cardiac output [87].3.4. Antisense oligonucleotide (ASO)
ASOs are synthetic nucleotides (15e25 nucleotides) that bind to
target mRNAs via Watson-Crick base paring and inhibit translation
of the encoded proteins. The two following mechanisms explainR-22, miR-33, miR-122, miR-126, miR-145, miR-155
15, miR-16, miR-17e92 cluster, miR-126, miR-130a, miR-210, miR-221
-15 family, miR-24, miR-29a, miR-30, miR-195, miR-199a, miR-590
-21, miR-26, miR-29, miR-133, miR-199a, miR-208, miR-408
-15, miR-138, miR-208, miR-218, miR-499
H. Chu et al. / Regenerative Therapy 4 (2016) 83e9188the inhibition: (i) steric hindrance prevents normal cellular ma-
chinery from performing splicing and translation; (ii) the nuclease
RNase H recognizes the complimentary strands and drives degra-
dation of the target mRNA [93]. Because of the size being short,
ASOs are made by solid-phase chemical synthesis in which modi-
ﬁed nucleotides are incorporated to increase pharmacokinetic
properties [94]. Substitution of the 20 hydroxyl group on the ribose
with a methoxyl or ﬂuoro group makes oligonucleotides nuclease-
resistant and increases their binding afﬁnity to mRNA targets [95].
Replacing the backbonewith a phosphorothioate linkage is another
common modiﬁcation used to prevent nucleolytic cleavage. ASOs
have been designed to target proteins whose overproduction is
closely related to MI. For example, the heat shock protein 47
(hsp47) drives the production of collagen and induces cardiac
remodeling [96]. Hagiwara S et al. employed an ASO to repress
hsp47 and revealed improved cardiac function in a rat MI model
[97]. ASOs have also been employed to reduce the risk of MI by
decreasing the level of apolipoprotein (A) in plasma [98]. The
versatility of ASOs suggests promise for their future utility as MI
therapeutics.
3.5. Aptamer
Aptamers are nucleic acid-based materials that selectively bind
to molecular targets such as proteins and small molecules. The
speciﬁcity of aptamers for particular proteins are screened by the
Systematic Evolution of Ligands by Exponential Enrichment
(SELEX) [99]. Like ASOs, aptamers can be made of single-stranded
DNA, RNA or their synthetic analogs (e.g. peptide nucleic acid)
[100]. Modiﬁcations on aptamer nucleotides are also important for
higher stability and binding afﬁnity [101]. The advantages of
aptamers include that their efﬁciency in molecular recognition
which can be on par with that of antibodies and their production
cost is comparatively low [102]. However, the binding afﬁnity of
aptamers results from their speciﬁc tertiary structures which can
be highly variable based on the environment. Selection processes
have to be well designed to mimic the in vivo conditions [103].
Aptamers may treat MI by binding to and inactivating proteins that
are overproduced. For example, anticoagulant therapy is employed
to prevent recurrent MI. In porcine and murine studies, Rusconi CP
et al. utilized an aptamer against factor IXa to inhibit coagulation
[104]. Its effect was rapidly reversed by introducing a compli-
mentary strand that inactivated the aptamer. As a result the po-
tential side effect of excessive bleeding was avoided. Inhibition of
vonWillebrand factor (VWF), which drives the coagulation cascade,
has been evaluated for the same purpose. In a clinical trial with
healthy volunteers, Gilbert JC et al. examined an aptamer inhibiting
VWF and demonstrated that the antithrombotic effect was both
dose and concentration dependent [105]. Their subsequent study
involving patients undergoing carotid endarterectomy conﬁrmed
its beneﬁt to reduce risk of thromboembolism [106]. Overall,
anticoagulation aptamers are considered a promising strategy for
many bleeding-associated disorders including stroke and MI [107].
3.6. CRISPR/Cas9
Genome engineering has become a popular ﬁeld in recent years.
It allows site-speciﬁc modiﬁcation of genetic information using a
variety of techniques including the Clustered Regularly Interspaced
Short Palindromic Repeat (CRISPR)/CRISPR-associated protein 9
(Cas9) system [108]. Different from protein-based genome editing
tools such as zinc-ﬁnger nucleases and transcription activator-like
effector nucleases (TALENs), CRISPR/Cas9 is a RNA-based system
in which a RNA fragment is responsible for specifying the DNA
target by complimentary pairing. CRISPR is a segment of DNAidentiﬁed in bacteria as a component of their adaptive immune
system. It contains DNA fragments from invading bacteriophages or
plasmids [109]. When the genomically-inserted DNA fragment is
transcribed, a long primary transcript (pre-crRNA) is formed. A
series of events follow to process the pre-crRNA into short RNAs
(crRNAs). The crRNA can complex with the Cas9 nuclease which is
also encoded in the CRISPR locus to direct cleavage of a DNA target
[110]. This process can be simply manipulated by co-expressing
Cas9 and a guide RNA (gRNA) that mimics the crRNA. Compared
to protein-based genome editing tools that employ proteins do-
mains to recognize the DNA target, CRISPR/Cas9 has the advantages
of simplicity because it avoids elaborate protein engineering pro-
cesses. It also enables multiplexing as several gRNAs can be intro-
duced to edit multiple genes simultaneously [111]. The main
disadvantage of CRISPR/Cas9, as compared to zinc-ﬁnger nucleases
and TALENs, is the higher frequency of off-target mutagenesis, and
new approaches are being developed to reduce this effect [112,113].
CRISPR/Cas9 is commonly introduced into cells by a viral vector
or a plasmid encoding the gRNA and Cas9 [114,115]. The synthetic
gRNA complexed with the Cas9 recombinant protein can also be
transfected into cells using the cationic lipid Lipofectamine [116].
Direct comparison revealed this approach had higher efﬁciency and
speciﬁcity than the plasmid-mediated method. Since CRISPR/Cas9
offers effective gene disruption, it has become a tool to reverse
cardiovascular diseases associated with genetic mutations. For
example, Ann Ran F et al. employed an adenoviral vector to deliver
the guide RNA and Cas9 to delete PCSK9 production in the mouse
liver. And the result indicated signiﬁcant reductions in serum Pcsk9
and total cholesterol (Fig. 2C) [117]. Apart from being a therapeutic
agent, CRISPR/Cas9 offers additional value of modeling heat dis-
eases and drug screening [118]. In this fashion, cardiomyocytes
derived from iPSCs are engineered to recapitulate the genetic
mutations in heart diseases followed by selection of an inhibitor
from a compound library [119].
4. Future perspective
The versatility of RNAs makes them highly attractive candidate
therapeutics formany human diseases. Successful translation to the
clinic relies on a deeper understanding of RNA biology including
exploring new classes of RNAs that hold therapeutic potential.
Long-noncoding RNAs (lncRNAs) represent an example. Distinct
from short non-coding RNAs that recognize targets through com-
plimentary base pairing, lncRNAs tend to fold into speciﬁc tertiary
structures and interact with proteins targets [120]. The biological
functions of lncRNAs are not fully understood but their importance
in cardiac development and the progression ofMI has been recently
revealed [121]. Thus, regulating the levels of long-noncoding RNAs
in attempt to reverse the diseased state and trigger the endogenous
regenerative process could be a promising direction in the future
[122,123].
As most diseases result from dysregulation of more than one
gene, administration of multiple therapeutic agents is often
necessary to bring more beneﬁts [124e126]. Combining RNA
therapeutics with protein or small molecule drugs has shown
promise. For example, siRNAs and small-molecule anticancer drugs
have been demonstrated to reduce drug resistance [127,128].
Combing RNA and protein therapies, Jeon SY et al. showed that co-
delivery of an siRNA and a transcription factor involved in chon-
drogenesis achieved higher efﬁciency in differentiating mesen-
chymal stem cells into chondrocytes than delivery of either single
agent [129]. Delivery of multiple RNAs to target different pathways
is another approach in treatment for MI.
Another direction is delivery of RNAs to improve cell-based
therapies. As adult cardiomyocytes have limited regenerative
H. Chu et al. / Regenerative Therapy 4 (2016) 83e91 89capacity, cell-based therapies are a promising approach to
replenish ischemic myocardium. Current protocols allow functional
cardiac tissues to be cultivated from iPSCs or ESCs in an efﬁcient
fashion [130]. They can later be implanted into a MI patient alone or
with a scaffold to recover cardiac function [131,132]. However, this
therapeutic approach has faced many challenges, particularly in
poor cell retention and survival in the infarcted region, and low
engraftment with the host tissue [133]. Incorporating an RNA agent
could provide the solution to these challenges. For example, mRNA
encoding angiogenic factors, and RNAi reducing inﬂammation and
ﬁbrosis in the host tissue may increase survival of delivered cells
[134]. To achieve this goal, a new strategy to effectively deliver cells
and RNAs is necessary.
Collectively, preclinical studies mostly in small animals have
demonstrated the value of RNA therapeutics in treating MI. Future
trials in large animals and patients will further explore their efﬁ-
cacy. Development of RNA-based MI therapeutics requires robust
design of the RNA agents to avoid adverse effects and optimal de-
livery strategies to maximize their beneﬁts.Conﬂict of interest
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